$2.19
0.052.34%
Últ. Act.: Nov 6, 4:00 PM
CytomX Therapeutics (CTMX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.09 | $-0.07 | -28.6 % |
| Q2 | Aug 6, 2026 | $-0.09 | $-0.10 | 10.0 % |
| Q1 | May 7, 2026 | $-0.10 | $-0.12 | 16.7 % |
| Q4 | Mar 16, 2026 | $-0.22 | $-0.09 | -144.4 % |
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.07 | $-0.10 | $-0.12 | $-0.09 |
| Actual | $-0.09 | $-0.09 | $-0.10 | $-0.22 |
| Surprise | -28.6% | +10.0% | +16.7% | -144.4% |
| Revenue | ||||
| Estimate | $9.2M | $11.3M | $4.4M | $7.3M |
| Actual | $1.7M | $1.4M | $10.3M | $663000 |
| Surprise | -81.7% | -87.5% | +130.8% | -91.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.10 | $-0.11 | $-0.12 | $-0.15 |
| Revenue | ||||
| Consensus | $5.1M | — | — | — |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $1.69M | $9.20M | -81.7 % |
| Q2 | Aug 6, 2026 | $1.42M | $11.31M | -87.5 % |
| Q1 | May 7, 2026 | $10.26M | $4.44M | 130.8 % |
| Q4 | Mar 16, 2026 | $663.00K | $7.34M | -91.0 % |